6533b870fe1ef96bd12cef91

RESEARCH PRODUCT

Matched-pairs analysis of outcomes with bortezomib, melphalan, and prednisone (VMP) treatment for previously untreated multiple myeloma (MM) using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

H. Van De VeldeDl EsseltineAna-isabel TeruelF De ArribaLixia PeiJ. Martínez-lópezLuis PalomeraJ F San MiguelM.v. MateosA. OriolEnrique BengoecheaAndrew Cakana

subject

MelphalanCancer Researchmedicine.medical_specialtyLong term follow upbusiness.industryBortezomibUrologyHematologyInterim analysismedicine.diseasecarbohydrates (lipids)OncologyPrednisoneMedian follow-uphemic and lymphatic diseasesToxicitymedicinebusinessneoplasmsMultiple myelomamedicine.drug

description

(95% CI: 58-88%), respectively. A formal interim analysis of the Day 90 CR rate was conducted when 65 patients were evaluable, and at that time the Mel only arm was determined to be superior. The study was, therefore, stopped early by the Institutional DSMB. However, with a longer follow up Bu-Mel ultimately resulted in better PFS. Conclusions: Bu-Mel was associated with a significantly lower day 90 CR rate and a significantly higher rate of grade 3-4 non-hematologic toxicity, compared to Mel. However, after a median follow up of 15.7 months, PFS was significantly longer in the Bu-Mel arm. Figure 1 PFS from Day 90 by Treatment Arm

yearjournalcountryeditionlanguage
2015-09-01Clinical Lymphoma Myeloma and Leukemia
https://doi.org/10.1016/j.clml.2015.07.224